Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Clinical trial NCT07498478 · RECRUITING
Trial details
- NCT number
- NCT07498478
- Sponsor
- TransThera Sciences (Nanjing), Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-17
- Primary completion
- 2027-06-30
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.